Meeting
2023 ASCO Gastrointestinal Cancers Symposium
INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
Authors
Nick Pavlakis
Royal North Shore Hospital, St Leonards, NSW, Australia;
Nick Pavlakis , Kohei Shitara , Katrin Marie Sjoquist , Andrew James Martin , Anthony Jaworski , Sonia Yip , Yung-Jue Bang , Thierry Alcindor , Christopher J. O'Callaghan , Niall C. Tebbutt , Andrew Strickland , Sun Young Rha , Keun-Wook Lee , John Raymond Zalcberg , Timothy Jay Price , John Simes , David Goldstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02773524
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr LBA294)
DOI
10.1200/JCO.2023.41.4_suppl.LBA294
Abstract #
LBA294
Poster Bd #
B13
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).
First Author: Katrin Marie Sjoquist
Poster
2015 ASCO Annual Meeting
LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
First Author: Heinz-Josef Lenz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).
First Author: Nick Pavlakis
Poster
2021 ASCO Annual Meeting
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
First Author: Yoshitaka Honma